首页> 外文期刊>Hypertension: An Official Journal of the American Heart Association >Paricalcitol and Endothelial Function in Chronic Kidney Disease TrialNovelty and Significance
【24h】

Paricalcitol and Endothelial Function in Chronic Kidney Disease TrialNovelty and Significance

机译:慢性肾脏疾病试验中的paricalcitol和内皮功能的研究及其意义

获取原文

摘要

Altered vitamin D metabolism and low levels of the active form of this vitamin, 1,25-dihydroxy-vitamin D, is a hallmark of chronic kidney disease (CKD), but there is still no randomized controlled trial testing the effect of active forms of vitamin D on vascular function in patients with CKD. Paricalcitol and ENdothelial fuNction in chronic kidneY disease (PENNY) is a double-blinded randomized controlled trial (ClinicalTrials.gov, [NCT01680198][1]) testing the effect of an active form of vitamin D, paricalcitol (2 μg/d×12 weeks) on endothelium-dependent and endothelium-independent vasodilatation in 88 patients with stage 3 to 4 CKD and parathormone >65 pg/mL (paricalcitol, n=44; placebo, n=44). Paricalcitol treatment reduced parathormone (?75 pg/mL; 95% confidence interval, –90 to –60), whereas parathormone showed a small rise during placebo (21 pg/mL; 95% confidence interval, 5–36). Blood pressure did not change in both study arms. Baseline flow-mediated dilation was identical in patients on paricalcitol (3.6±2.9%) and placebo (3.6±2.9%) groups. After 12 weeks of treatment, flow-mediated dilation rose in the paricalcitol but not in the placebo group, and the between-group difference in flow-mediated dilation changes (the primary end point, 1.8%; 95% confidence interval, 0.3–3.1%) was significant ( P =0.016), and the mean proportional change in flow-mediated dilation was 61% higher in paricalcitol-treated patients than in placebo-treated patients. Such an effect was abolished 2 weeks after stopping the treatment. No effect of paricalcitol on endothelium-independent vasodilatation was registered. Paricalcitol improves endothelium-dependent vasodilatation in patients with stage 3 to 4 CKD. Findings in this study support the hypothesis that vitamin D may exert favorable effects on the cardiovascular system in patients with CKD.# Novelty and Significance {#article-title-37} [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01680198&atom=%2Fhypertensionaha%2F64%2F5%2F1005.atom
机译:维生素D代谢改变和该维生素1,25-二羟基维生素D的活性形式水平低是慢性肾脏病(CKD)的标志,但仍没有随机对照试验来测试维生素D的活性形式的作用维生素D对CKD患者血管功能的影响。慢性肾病中的帕立骨化醇和肠上皮功能(PENNY)是一项双盲随机对照试验(ClinicalTrials.gov,[NCT01680198] [1]),用于测试维生素D活性形式帕立骨化醇(2μg/ d×12)的作用周)对88例3至4期CKD,副激素> 65 pg / mL的患者进行了内皮依赖性和非内皮依赖性血管舒张(paricalcitol,n = 44;安慰剂,n = 44)。 Paricalcitol治疗降低了副甲状腺激素(?75 pg / mL;置信区间为95%,从–90至–60),而副甲状腺激素在安慰剂期间显示出少量上升(21 pg / mL; 95%置信区间为5–36)。两个研究组的血压均未改变。 Paricalcitol(3.6±2.9 %)和安慰剂组(3.6±2.9 %)组的基线血流介导的扩张作用相同。治疗12周后,帕立骨化醇中的血流介导的扩张增加,而安慰剂组则没有,组间血流介导的扩张的差异改变(主要终点为1.8%,置信区间为95%,0.3 –3.1 %)具有显着意义(P = 0.016),而接受paricalcitol治疗的患者血流介导的扩张平均比例变化比安慰剂治疗的患者高61%。停止治疗后2周,这种作用消失了。没有记录paricalcitol对非内皮依赖性血管舒张的影响。 Paricalcitol可改善3至4期CKD患者的内皮依赖性血管舒张。这项研究的发现支持以下假设:维生素D可能会对CKD患者的心血管系统产生有利影响。#新颖性和意义{#article-title-37} [1]:/ lookup / external-ref?link_type = CLINTRIALGOV&access_num = NCT01680198&atom = %2Fypertensionaha %2F64 %2F5 %2F1005.atom

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号